Table 1.
Clinical and demographic characteristics of UC patients from cohort 1. Patients with UC are divided into active or remission, based on their endoscopic Mayo scores. Continuous variables are described as median and IQR, and categorical variables as absolute frequencies and percentages; p-values from non-parametric tests are shown.
| Cohort 1: Clinical and demographic characteristics | |||
|---|---|---|---|
| Active UC | Remission UC | p-Value | |
| Total | 103 | 33 | — |
| Microarray [Group 1] | |||
| Total | 17 | 8 | — |
| Gender | 0.39 | ||
| Male | 12 [70.6%] | 4 [50%] | |
| Female | 5 [29.4%] | 4 [50%] | |
| Age [years] | 45 [35–54] | 52 [43–57] | 0.22 |
| Duration of disease [years] | 9 [3–12] | 13 [13–22] | < 0.01 |
| Extent of disease | 0.14 | ||
| Proctitis | 1 [5.9%] | 3 [37.5%] | |
| Left-sided colitis | 12 [70.6%] | 3 [37.5%] | |
| Extensive colitis | 4 [23.5%] | 2 [25%] | |
| Medication | 0.88 | ||
| No treatment | 2 [11.8%] | 2 [25%] | |
| 5-ASA | 10 [58.8%] | 5 [62.5%] | |
| Immunosuppressors | 2 [11.8%] | 1 [12.5%] | |
| Anti-TNF | 2 [11.8%] | 0 [0%] | |
| Steroids | 1 [5.9%] | 0 [0%] | |
| Combined therapy | 0 [0%] | 0 [0%] | |
| CRP [mg/dL] | 1.1 [0.3–1.8] | 0.2 [0.02–0.3] | < 0.01 |
| ESR [mm/h] | 16.0 [7.0–22.8] | 16.0 [12.0–18.3] | 0.94 |
| Platelet count [10^9/L] | 320 [291–381] | 233 [189–386] | 0.14 |
| Global Mayo Score | 7 [5–8] | 0 [0–0] | < 0.01 |
| Endoscopic Mayo Score | — | ||
| Score 0 | 0 [0%] | 8 [100%] | |
| Score 1 | 1 [5.9%] | 0 [0%] | |
| Score 2 | 4 [23.5%] | 0 [0%] | |
| Score 3 | 12 [70.6%] | 0 [0%] | |
| N/L Ratio | 3.3 [2.6–3.5] | 2.6 [2.2–2.9] | 0.20 |
| Real-Time PCR [Group 2] | |||
| Total | 86 | 25 | — |
| Gender | 0.25 | ||
| Male | 53 [61.6%] | 12 [48%] | |
| Female | 33 [38.4%] | 13 [52%] | |
| Age [years] | 45 [36–56] | 50 [37–60] | 0.42 |
| Duration of disease [eayrs] | 9 [4–15] | 15 [11–23] | < 0.01 |
| Extent of disease | 0.38 | ||
| Proctitis | 21 [24.4%] | 3 [12%] | |
| Left-sided colitis | 25 [29.1%] | 9 [36%] | |
| Extensive colitis | 40 [46.5%] | 13 [52%] | |
| Medication | 0.07 | ||
| No treatment | 4 [4.7%] | 4 [16%] | |
| 5-ASA | 32 [37.2%] | 13 [52%] | |
| Immunosuppressors | 18 [20.9%] | 5 [20%] | |
| Anti-TNF | 7 [8.1%] | 2 [8%] | |
| Steroids | 11 [12.8%] | 0 [0%] | |
| Combined therapy | 14 [16.3%] | 1 [4%] | |
| CRP [mg/dL] | 0.84 [0.17–2.24] | 0.12 [0.03–0.5] | < 0.01 |
| ESR [mm/h] | 11.5 [7.0–26.5] | 10.0 [5.5–15.5] | 0.25 |
| Platelet count [10^9/L] | 279 [228–323] | 252 [194–273] | 0.03 |
| Global Mayo Score | 6 [2–8.8] | 0 [0–0] | < 0.01 |
| Endoscopic Mayo Score | — | ||
| Score 0 | 0 [0%] | 25 [100%] | |
| Score 1 | 24 [27.9%] | 0 [0%] | |
| Score 2 | 21 [24.4%] | 0 [0%] | |
| Score 3 | 41 [47.7%] | 0 [0%] | |
| MS | 4 [2–7.8] | 0 [0–0] | — |
| Neutrophils [%] | 64.5 [57.1–68.7] | 61 [54.5–68.2] | 0.27 |
| Neutrophil count [10^9/L] | 3.9 [3.0–5.9] | 3.6 [2.9–4.9] | 0.28 |
| N/L ratio | 2.8 [1.9–3.2] | 2.1 [1.5–3.1] | 0.16 |
UC, ulcerative colitis; IQR, interquartile range; 5-ASA, 5-aminosalicylic acid; TNF, tumour necrosis factor;CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RT-PCR, real-time polymerase chain reaction; N/L ratio; neutrophil-lymphocyte ratio; MS; Modified Score [sum of endoscopic Mayo score of each segment], only available for patients with complete endoscopy procedure [n = 95].